Hugh J. B. Goodman

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis

Ashutosh Wechalekar, Hugh J. B. Goodman, Helen J. Lachmann et al. · Blood · 2006 · 231 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +3

Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis

Julian D. Gillmore, Glenys A. Tennent, Winston L. Hutchinson et al. · British Journal of Haematology · 2010 · 138 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis

Julian D. Gillmore, Hugh J. B. Goodman, Helen J. Lachmann et al. · Blood · 2005 · 131 citations · Full text

Medicine, Cardiology, Internal Medicine +11

Outcome of autologous stem cell transplantation for AL amyloidosis in the UK

Hugh J. B. Goodman, Julian D. Gillmore, Helen J. Lachmann et al. · British Journal of Haematology · 2006 · 87 citations

Medicine, Oncology, Cell Therapy +14